A carregar...

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma

BACKGROUND: The aim of the study was to investigate the temporary combination of anti-PD-1 plus targeted therapy followed by single targeted therapy in advanced renal cell carcinoma (RCC) as second-line therapy. METHODS: A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Androl Urol
Main Authors: Lu, Xiaolin, Gu, Weijie, Shi, Guohai, Ye, Dingwei
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8185682/
https://ncbi.nlm.nih.gov/pubmed/34159088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tau-21-338
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!